Clinical Trial: Efficacy and Safety of Adjuvant Trastuzumab Rezetecan in Patients with Early HER2-Positive Breast Cancer without Pathologic Complete Response Following Neoadjuvant Therapy (China)

Posted On: 2026-08-18

China, Aug. 18 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Efficacy and Safety of Adjuvant Trastuzumab Rezetecan in Patients with Early HER2-Positive Breast Cancer without Pathologic Complete Response Following Neoadjuvant Therapy'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130239

Registration Time: 2026/08/17

Type: Interventional study

Primary Sponsor: The First Affiliated Hospital of Wenzhou Medical University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=338718

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: Efficacy and Safety of Adjuvant Trastuzumab Rezetecan in Patients with Early HER2-Positive Breast Cancer without Pathologic Complete Response Following Neoadjuvant Therapy (China)